LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

Search

Kura Oncology Inc

Open

SectorGezondheidszorg

7.92 -4.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.98

Max

8.35

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.7M

-66M

Verkoop

1.2M

15M

Winstmarge

-432.509

Werknemers

192

EBITDA

-8M

-73M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+188.32% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

139M

686M

Vorige openingsprijs

12.27

Vorige sluitingsprijs

7.92

Nieuwssentiment

By Acuity

50%

50%

173 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 sep 2025, 23:59 UTC

Acquisities, Fusies, Overnames

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sep 2025, 22:02 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Tron Shares Rise After New Investment From Bravemorning

8 sep 2025, 16:14 UTC

Belangrijke Marktbewegers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sep 2025, 16:13 UTC

Belangrijke Marktbewegers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sep 2025, 23:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sep 2025, 22:56 UTC

Marktinformatie

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sep 2025, 22:23 UTC

Marktinformatie

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sep 2025, 21:51 UTC

Marktinformatie

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sep 2025, 21:47 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4B AI Deal With Nebius

8 sep 2025, 21:33 UTC

Acquisities, Fusies, Overnames

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sep 2025, 21:20 UTC

Acquisities, Fusies, Overnames

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sep 2025, 21:19 UTC

Acquisities, Fusies, Overnames

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sep 2025, 21:18 UTC

Acquisities, Fusies, Overnames

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 19:33 UTC

Marktinformatie

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sep 2025, 19:22 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sep 2025, 19:02 UTC

Marktinformatie

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sep 2025, 17:29 UTC

Marktinformatie

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sep 2025, 16:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sep 2025, 16:36 UTC

Marktinformatie

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sep 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 16:16 UTC

Winsten

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 sep 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

188.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 23.7 USD  188.32%

Hoogste 40 USD

Laagste 7.95 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

173 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat